Abstract
Kynurenic acid (KYNA), one of the metabolites belonging to the kynurenine pathway, has been described as an important neuroprotective compound, its unbalancing being associated with several pathological conditions. In human brain, the majority of KYNA production is sustained by kynurenine aminotransferase II (KAT II). A selective KAT II inhibitor would be an important pharmacological tool, since it would reduce KYNA formation without causing complete depletion of this neuroprotector. (S)-(4)-(ethylsulfonyl)benzoylalanine (S-ESBA), described as a potent and selective inhibitor of rat KAT II, is unfortunately ineffective towards the human enzyme although the two orthologs share a remarkably high degree of sequence identity. We investigated the molecular basis for this intriguing species-specificity by adopting a site-directed mutagenesis and structural approach. We propose that the source of the inhibitor specificity toward the rat enzyme could reside on S-ESBA interaction/interference with a flexible loop that controls ligand admission to the active site by a classical induced-fit mechanism. Our data further highlights that even in case of highly conserved molecular targets, the flexibility of catalytically important structural elements can have a significant impact on the selectivity of inhibitor action.
Keywords: Kynurenic acid, kynurenine aminotransferase II, PLP-enzymes, crystal structure, conformational flexibility, drug design, cognition enhancing drugs, drug selectivity, S-ESBA, ligand, L-tryptophan, mammals, kynurenines, neuroactive, NMDA receptor, 7 nicotinic receptor, schizophrenia, Neurochemistry studies, dopamine, PLP-KYN, ketoacid, PMP, KAT II, mAAT, L-KYN, QUIN, hKAT II, Asp230, Tyr233, Tyr74, Arg399, isozymes, enzymes, PCR-based, homogeneity, X-ray, DNA sequencing, oligomeric, Bradford assay, albumine, Protein aliquots, UV/HPLC, ESRF, MOSFLM, SCALA, 3OH-KYN, ketoglutarate, IC50 value, catalysis, kinetics, mutant, wild-type, co-crystallization, stabilization, N-terminal
Current Topics in Medicinal Chemistry
Title: Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?
Volume: 11 Issue: 2
Author(s): Valentina Casazza, Franca Rossi and Menico Rizzi
Affiliation:
Keywords: Kynurenic acid, kynurenine aminotransferase II, PLP-enzymes, crystal structure, conformational flexibility, drug design, cognition enhancing drugs, drug selectivity, S-ESBA, ligand, L-tryptophan, mammals, kynurenines, neuroactive, NMDA receptor, 7 nicotinic receptor, schizophrenia, Neurochemistry studies, dopamine, PLP-KYN, ketoacid, PMP, KAT II, mAAT, L-KYN, QUIN, hKAT II, Asp230, Tyr233, Tyr74, Arg399, isozymes, enzymes, PCR-based, homogeneity, X-ray, DNA sequencing, oligomeric, Bradford assay, albumine, Protein aliquots, UV/HPLC, ESRF, MOSFLM, SCALA, 3OH-KYN, ketoglutarate, IC50 value, catalysis, kinetics, mutant, wild-type, co-crystallization, stabilization, N-terminal
Abstract: Kynurenic acid (KYNA), one of the metabolites belonging to the kynurenine pathway, has been described as an important neuroprotective compound, its unbalancing being associated with several pathological conditions. In human brain, the majority of KYNA production is sustained by kynurenine aminotransferase II (KAT II). A selective KAT II inhibitor would be an important pharmacological tool, since it would reduce KYNA formation without causing complete depletion of this neuroprotector. (S)-(4)-(ethylsulfonyl)benzoylalanine (S-ESBA), described as a potent and selective inhibitor of rat KAT II, is unfortunately ineffective towards the human enzyme although the two orthologs share a remarkably high degree of sequence identity. We investigated the molecular basis for this intriguing species-specificity by adopting a site-directed mutagenesis and structural approach. We propose that the source of the inhibitor specificity toward the rat enzyme could reside on S-ESBA interaction/interference with a flexible loop that controls ligand admission to the active site by a classical induced-fit mechanism. Our data further highlights that even in case of highly conserved molecular targets, the flexibility of catalytically important structural elements can have a significant impact on the selectivity of inhibitor action.
Export Options
About this article
Cite this article as:
Casazza Valentina, Rossi Franca and Rizzi Menico, Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?, Current Topics in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/156802611794863599
DOI https://dx.doi.org/10.2174/156802611794863599 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FtsZ: A Novel Target for Tuberculosis Drug Discovery
Current Topics in Medicinal Chemistry The Influence of Erythropoietin and Proinflammatory Cytokines in the Development of Cerebral Palsy
Vascular Disease Prevention (Discontinued) Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Drivers’ Visual Scanning Impairment Under the Influences of Alcohol and Distraction: A Literature Review
Current Drug Abuse Reviews Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Current Medicinal Chemistry The Psychoactive Effects of Antidepressants and their Association with Suicidality
Current Drug Safety Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Chaperones that Protect Tetrahydrobiopterin Dependent Aromatic Amino Acid Hydroxylases Through Different Mechanisms
Current Drug Targets Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics
Current Topics in Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Architectural Changes of Thigh Muscles in Patients with Subacute Stroke after Body Weight Support Treadmill Training
Current Medical Imaging Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Molecular and Biochemical Features of the Mitochondrial Enzyme Ornithine Transcarbamylase: A Possible New Role as a Signaling Factor
Current Medicinal Chemistry Clinical Management of Secretion Retention in Critically Ill Patients who are Intubated and Mechanically Ventilated
Current Respiratory Medicine Reviews The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Gelatin Tannate: A Selective Biofilm-Forming, Gut Mucoprotectant for Acute Gastroenteritis in Children. A Short Narrative Review
Current Drug Therapy